logo
Sign in

GLMD Stock Price, Chart, Stats & News

Galmed Pharmaceuticals Ltd.
Save
3.18M
Market cap
Current P/E
Forward P/E

GLMD chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
Operating margin
Pretax margin
Net margin
Effective tax rate
ROA
-40.31%
ROE
-47.78%
D/E
Interest coverage ratio
-15.70x

GLMD valuation

P/E
P/S
P/B
0.14x
P/CF
-0.43x
P/FCF
-0.44x
P/OCF
-0.43x
PEG
-0.01x
EV multiple
-0.86x

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for liver diseases. Its primary pipeline candidate is Aramchol, an orally administered drug currently undergoing Phase III clinical trials. This pivotal study is for the treatment of non-alcoholic steato-hepatitis (NASH) in individuals who are overweight or obese and also present with pre-diabetes or type 2 diabetes.

Similar securities

Based on sector and market capitalization

Report issue